DSS Document Security Systems Inc.

DSS Inc. Appoints Daniel Lew as Chief Investment Officer and Portfolio Manager for DSS Wealth, Inc.

DSS Inc. Appoints Daniel Lew as Chief Investment Officer and Portfolio Manager for DSS Wealth, Inc.

ROCHESTER, N.Y., July 05, 2023 (GLOBE NEWSWIRE) -- DSS Wealth, Inc., a wholly owned subsidiary of DSS, Inc. and advisor to DSS AmericaFirst Quantitative Funds, is pleased to announce the appointment of Daniel Lew as Chief Investment Officer and Portfolio Manager. With over three decades of experience in investment management, security analysis, and institutional client advisory, Mr. Lew brings a wealth of knowledge and expertise to his new role.

Mr. Lew's distinguished career spans various prestigious financial institutions, where he has held senior investment management positions. Prior to joining DSS Wealth, Inc., he served as a key contributor at AIG SunAmerica, Strong Capital, John Hsu Capital, Citizens Advisers, and Equitable Capital. He has also worked as an investment consultant for institutional funds at William M. Mercer and RogersCasey.

As Chief Investment Officer, Mr. Lew will be responsible for overseeing DSS Wealth's investment strategies, ensuring the optimal allocation of resources, and managing risk to achieve clients' financial goals. Additionally, as Portfolio Manager, he will leverage his extensive experience to drive the firm's investment decisions and generate superior returns for clients.

With a deep understanding of financial markets and a proven track record, Mr. Lew has earned the right to use the prestigious Chartered Financial Analyst (CFA) designation. He holds a Bachelor of Science degree in Computer Science from Columbia University School of Engineering and Applied Science, as well as a Master of Business Administration (MBA) in finance from NYU, Stern Graduate School of Business.

"We are thrilled to welcome Daniel Lew to our team as Chief Investment Officer and Portfolio Manager," said Jason Grady, Chief Operating Officer at DSS, Inc. "His extensive experience, track record, impressive credentials, and demonstrated expertise make him an invaluable addition to our firm. We are confident that under his leadership, our investment strategies will deliver exceptional results for our clients."

Daniel Lew's appointment at DSS Wealth, Inc. represents the firm's commitment to attracting industry-leading talent and further enhancing its position as a trusted financial partner for individuals and institutions alike. His arrival reinforces DSS Wealth's dedication to providing exceptional investment solutions and personalized service to its diverse client base.

About DSS, Inc.

DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Consumer Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to increase shareholder value through periodic IPO spinoffs. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors.

For more information on DSS visit and .

About DSS Wealth, Inc.

DSS Wealth Management recently assumed the role of Advisor to the AmericaFirst Quantitative Funds. Utilizing a unique quantitative approach to investing, DSS AmericaFirst offers structure, process and tools designed to help achieve investment goals.

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company's intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in our SEC filings, including, without limitation, our reports on Forms 8-K, 10-K and 10-Q, all of which can be obtained on the SEC website at . Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact:

DSS Inc. Investor Relations

+1 (585) 565-2422



EN
05/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Document Security Systems Inc.

 PRESS RELEASE

Sentinel Brokers Company, Inc., a Subsidiary of DSS, Inc., Receives FI...

Sentinel Brokers Company, Inc., a Subsidiary of DSS, Inc., Receives FINRA Approval to Act as Underwriter and Selling Group Member for Corporate Securities Offerings NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Sentinel Brokers Company, Inc. (“Sentinel”), a FINRA-registered broker-dealer and a subsidiary of DSS, Inc. (NYSE American: DSS), is pleased to announce that it has received approval from the Financial Industry Regulatory Authority (FINRA) to act as an underwriter and selling group member for corporate securities offerings. This regulatory milestone significantly enhances Sentinel’...

 PRESS RELEASE

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining...

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE American: IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS’ ongoing strategy to optimize its portfolio and concentrate on core growth areas. Celios® is a cutting-edge air purifi...

 PRESS RELEASE

DSS, Inc. Issues Letter to Shareholders

DSS, Inc. Issues Letter to Shareholders NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) a multinational company operating businesses within diversified market sectors that strategically acquires and develops assets to increase shareholder value, today issued the following letter to shareholders: Dear Esteemed Shareholders, I am pleased to provide you with significant updates regarding the leadership of DSS, Inc. and to outline the strategic direction we are pursuing as a Company. It is with great honor that I announce my appointment as Interim Chief Executive...

DSS Inc: 1 director

A director at DSS Inc bought 1,025,746 shares at 0.975USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proud...

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol “IBO,” these shares will b...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch